The human gene Hugl-1 (Llgl/Lgl1) has significant homology to the Drosophila tumor suppressor gene lethal(2)giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that is involved in maintaining cell polarity and epithelial integrity. We speculate that Hugl-1 might play a role in epithelialmesenchymal transition (EMT) and that loss of Hugl-1 expression plays a role in the development or progression of malignant melanoma. Thus, we evaluated melanoma cell lines and tissue samples of malignant melanoma for loss of Hugl-1 transcription. We found that Hugl-1 was downregulated or lost in all cell lines and in most of the tumor samples analysed, and that these losses were associated with advanced stage of the disease. Reduced Hugl-1 expression occurred as early as in primary tumors detected by both immunohistochemical and reverse transcription-polymerase chain reaction (RT-PCR) analysis. Functional assays with stable Hugl-1-transfected cell lines revealed that Hugl-1 expression increased cell adhesion and decreased cell migration. Further, downregulation of MMP2 and MMP14 (MT1-MMP) and re-expression of E-cadherin was found in the Hugl-1-expressing cell clones supporting a role of Hugl-1 in EMT. Our studies thus indicate that loss of Hugl-1 expression contributes to melanoma progression.
Introduction
Malignant melanoma is a highly aggressive cancer derived from melanocytes mainly in the epidermis. Some information about processes involved in tumor development is known today, but the molecular cause of the disease still remains unsolved. Recent data indicated that loss of cell-cell and cell-matrix contact and changes in the cell cytoskeletal organization play an important role in the early development of the disease (Danen et al., 1995; Hendrix et al., 1996; Jankowski et al., 1997) . Additionally, proteins known to be involved in epithelial-mesenchymal transition (EMT), such as E-cadherin, matrix metalloproteinases (MMPs), etc, were found to be deregulated (Gilles et al., 1997a, b; Tester et al., 2000; Pla et al., 2001) .
The human gene Hugl-1 has significant homology to the Drosophila tumor suppressor gene lethal(2)giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that is involved in maintaining cell polarity and epithelial integrity. The human protein, Hugl-1, contains several conserved functional domains found in Lgl including homo-oligomerization domains, a cluster of phosphorylation sites, at least two WD-40 repeats suggesting these proteins may have closely related functions (Kalmes et al., 1996; Grifoni et al., 2004) . Loss of lgl in Drosophila results in the neoplastic transformation of the imaginal discs, which lose their epithelial monolayer structure and grow in large amorphous masses resembling mammalian carcinomas (Agrawal et al., 1995) . Upon transplantation into wildtype recipients, these tumorous tissues behave like mammalian metastatic tumors (Woodhouse et al., 1994 (Woodhouse et al., , 1998 . Metastases overexpress type IV collagenase and nucleoside diphosphate kinase (NDP kinase), thus showing some of the biochemical features of metastatic tumors in humans (Timmons et al., 1993; Woodhouse et al., 1994) .
Homologs of lgl have been identified in many species including man (Hugl-1) and mouse (mgl-1) (Tomotsune et al., 1993; Strand et al., 1995) . The tumor suppressor function is conserved between fruit flies and humans since Hugl-1 can rescue Drosophila lgl mutants. (Grifoni et al., 2004) . Biochemical and genetic analyses have shown that the Lgl proteins are components of the cytoskeleton (Strand et al., 1994a, b) . Recently, evidence was provided that mammalian Lgl forms complexes with Par6/atypical PKC regulating epithelial cell polarity (Plant et al., 2003; Yamanaka et al., 2003) . Upon cell-cell contact-induced cell polarization, Lgl is phosphorylated by atypical protein kinase C (aPKC) resulting in a dissociation of Lgl from Par6/ aPKC followed by an accumulation of Lgl along the basolateral membrane, where it contributes to the formation of the basolateral membrane domain (Tanentzapf and Tepass, 2003; Hutterer et al., 2004) and to correct positioning of epithelial junctions (Borg, 2004) . Additionally, recent studies revealed that Lgl has the ability to inhibit notch signaling (Justice et al., 2003) .
We have recently investigated a panel of 60 human solid tumors and reported that Hugl-1 is reduced or absent in 62% of the samples examined (Grifoni et al., 2004) . In a series of 94 colon carcinomas, we found that Hugl-1 expression was altered in 75% of the samples and the reduction in Hugl-1 correlated with disease progression (Schimanski et al., 2005) . Taken together with the data presented in this paper, a tumor suppressor role for Hugl-1 in humans is likely. The present study was performed to evaluate the role of Hugl-1 in human malignant melanoma development and progression. Therefore, we screened the transcription profiles of Hugl-1 in nine different human melanoma cell lines and 15 melanoma tissue samples and performed immunohistochemical (IHC) staining on nevi, primary melanoma and metastases. In addition, functional assays with a Hugl-1 re-expressing melanoma cell line were performed to characterize the biological effects of Hugl-1.
Results
Loss of Hugl-1 transcription during melanoma development Nine human melanoma cell lines were evaluated for expression of Hugl-1 mRNA using quantitative polymerase chain reaction (PCR) and compared to human primary melanocytes (NHEM). Strong reduction or loss of expression was found in all melanoma cell lines compared to melanocytes (Figure 1a ).
Since loss of chromosome 17p containing Hugl-1 is rarely affected in malignant melanoma, we hypothesized that promoter hypermethylation could have silenced gene expression. All cell lines were exposed to 5-azacytidine for demethylation and Hugl-1 expression was quantified. Our results showed no upregulation of Hugl-1 expression after demethylation in all cell lines except Mel Wei. This indicates that expression of Hugl-1 is most likely downregulated by transcriptional control of the promoter (Figure 1b) . Further studies must be perfomed to identify transcription factors involved in this regulation.
To locate the loss of Hugl-1 within the development of malignant melanoma, RNAs isolated from four primary melanomas, seven lymph node metastases and five distant metastases by microdissection were screened by quantitative RT-PCR. Reduction of Hugl-1 transcription was observed in two of four primary melanomas, five of seven lymph node and all distant metastases analysed when compared to expression levels in normal skin and in isolated normal human epidermal melanocytes (NHEM) (Figure 1c) .
The nine different melanoma cell lines were further screened for Hugl-1 protein expression by Western blotting using anti-Hugl-1-antibody (Figure 1d ). Consistent with the reduced amount of mRNA expression, only weak levels of Hugl-1 protein were detected in all the melanoma cell lines compared to primary human melanocytes. In summary, both the results from quantitative reverse transcriptase-PCR (RT-PCR) and Western blots indicate reduced Hugl-1 expression in melanoma cells.
To examine Hugl-1 expression in vivo, 15 tissue samples from patients with benign melanocytic nevi, primary malignant melanomas and metastatic malignant melanomas were immunostained with an antiHugl-1 antibody. Representative sections are presented in Figure 1e . Hugl-1 expression in keratinocytes has not been described previously but was verified by RT-PCR. The intensity and the percentage of Hugl-1 positive cells were reduced in primary malignant melanoma (III-V) compared to normal skin (I) and nevi (II). In nevi no differences comparing junctional or dermal nevi were determined. In metastases (VI), further reduction of expression was seen and with the exception of very few cases semiquantitative immunoscoring discriminated benign from malignant melanocytic tumors. In summary, these data show an inverse correlation between protein expression and tumor progression as the amount of Hugl-1 protein staining decreases from nevus to metastatic melanoma in vivo.
Functional relevance of loss of Hugl-1 expression To analyse the functional role of Hugl-1 in melanoma cells, we restored expression of Hugl-1 in the melanoma cell line Mel Im by stable transfection with a Hugl-1 expression construct. Successful re-expression of Hugl-1 in the cell clones (4, 5 and 9) was shown by quantitative RT-PCR ( Figure 2a ) and Western blotting (Figure 2b ), whereas no changes of Hugl-1 expression were seen in two control transfected cell clones (mock 1 and 2).
To study the functional relevance of Hugl-1 expression several different assays were performed. Proliferation assays revealed no changes in proliferation comparing the Hugl-1-expressing cell clones to the controls and wild-type Mel Im cells (data not shown). Additionally, colony formation assays to evaluate the ability for anchorage-independent growth showed no differences between the Hugl-1 re-expressing cell clones and the mock controls (data not shown).
Interestingly, migration and invasion assays using the Boyden Chamber system showed a strong reduction of the migratory and invasive potential in the Hugl-1 re-expressing cell clones (Figure 3a and b). The mock transfected Mel Im cell clones did not show significant changes in invasiveness, whereas Hugl-1 transfected cell clones (clone 4, 5 and 9) displayed significantly reduced migration and invasiveness in comparison to the controls. To further evaluate the effect of Hugl-1 on migration, wound healing assays (scratch assays) were performed. Again, a strong reduction in the migratory ability of the Hugl-1-expressing melanoma cell clones was demonstrated (Figure 3c ). Hugl-1-expressing cell clones revealed a reduction of migration of 59% (712%) compared to mock-transfected controls. Attachment assays revealed enhanced adhesion of the Reduced expression of Hugl-1 in malignant melanoma S Kuphal et al
Hugl-1-expressing cell clones compared to mocktransfected cells (data not shown). Taken together, Hugl-1 expression does not affect cell proliferation or anchorage-independent growth, but decreases cell migration and enhances cell attachment. These results suggest that reduced Hugl-1 expression may destabilize epithelial structures and contribute to cancer cell dissemination and, ultimately, tumor progression. In melanoma cell lines the expression was reduced. As loading control the blot was counterstained with a b-actin antibody.
(e) Immunostaining of Hugl-1 revealed strong cytoplasmatic and membranous immunosignals in normal skin and benign melanocytic nevi (I, II), reduced or loss of expression in primary tumors (III, IV, V) and complete loss of Hugl-1 expression in metastases of malignant melanomas (VI).
Reduced expression of Hugl-1 in malignant melanoma S Kuphal et al Differences in gene expression in Hugl-1-expressing cell clones After observing the strong effect on invasion and migration when Hugl-1 is expressed in melanoma cells, genes potentially involved in these processes were analysed. MMP-14 (MT1-MMP) and MMP-9 are known to play a role in melanoma invasion. Expression of these genes was evaluated by quantitative RT-PCR (Figure 4a and b) . Downregulation of expression of MMP-9 and MMP-14 was found in the Hugl-1-expressing cell clones. As we speculated that Hugl-1 may play a role in EMT, we analysed E-cadherin expression. This cell-cell adhesion molecule is important in organizing epithelial structures and its expression is lost during EMT when cells change into a migratory, 'mesenchymal' cell form. Loss of E-cadherin expression is an early and important process in the development of malignant melanoma. Quantitative RT-PCR revealed upregulation of E-cadherin expression in the stable transfected melanoma cell clones expressing Hugl-1 (Figure 5a ). This finding was supported by Western blot analysis (Figure 5b ). Additionally, immunofluorescence observations revealed staining of Hugl-1 and of E-cadherin in the Hugl-1-expressing cell clones, whereas no expression of both molecules was observed in the wild-type Mel Im cell line and the mock-transfected cell clone (Figure 5c ). Hugl-1-expressing cells showed a membranous and cytoplasmatic Hugl-1 staining. Interestingly, the cell clones seem to show enhanced cell-cell attachment due to E-cadherin expression.
To focus on a role of Hugl-1 in EMT, additional molecules known to be regulated in EMT, for example, by the transcription factor snail in melanoma (Kuphal et al., 2005) , were analysed. Quantitative RT-PCR revealed strong reduction of expression of fibronectin (46%73.65 compared to mock set as 100%) notch4 (47%76.25 compared to mock set as 100%), and bcatenin (63%72.8 compared to mock set as 100%) in Reduced expression of Hugl-1 in malignant melanoma S Kuphal et al the Hugl-expressing cell clones compared to the wildtype or mock-transfected cells.
Discussion
In this study we investigated the transcription profile of Hugl-1, the human homolog of the Drosophila tumor suppressor lgl, in malignant melanoma. We initiated this study to explore the possibility that Hugl-1 may play a role in cell polarity and EMT in this disease. Specifically, Expression of E-cadherin in Hugl-1-expressing cell clones. (a) By real-time PCR the amount of E-cadherin mRNA expression was quantified in the cell clones. The mock-transfected cell clones showed no expression of E-cadherin compared to normal human epidermal melanocytes (NHEM), whereas induction of E-cadherin expression was found in the Hugl-1-expressing cell clones. (b) By Western blot analysis expression of E-cadherin protein was detected in the Hugl-1-expressing cell clones. As loading control, the blot was counterstained with a b-actin antibody. (c) By immunofluorescence staining, expression of Hugl-1 and E-cadherin was shown in the cell clones whereas no expression of both proteins was seen in the wild-type Mel Im cell line and in the mock-transfected clone mock 1.
Reduced expression of Hugl-1 in malignant melanoma S Kuphal et al we were interested to know whether Hugl-1 transcription is altered during melanoma development and progression and whether loss of Hugl-1 expression correlates with tumor characteristics. Our data indicated that loss of Hugl-1 expression has an impact on melanoma development and progression. We found Hugl-1 transcription was reduced in all nine melanoma cell lines examined on mRNA and protein levels. Additionally, reduction or loss of Hugl-1 expression was also found in situ in primary melanoma, lymph node metastases and distant melanoma metastases. The amount of Hugl-1 protein staining decreased from normal skin to metastatic melanoma. In functional assays we could show that induction of expression of Hugl-1 protein resulted in a significant decrease in cell migration and stress-induced cellular detachment, but did not influence proliferation. Thus, downregulation of Hugl-1 may contribute to the dissemination of cancer cells. In Drosophila, effects of the lgl mutation on cell proliferation have been extensively described; however, the reasons for this effect are unknown. Obviously, re-expression of Hugl-1 and hereby modulating signaling pathways is not enough to negatively regulate proliferation as changes in several cellular pathways lead to upregulation of cell proliferation in human malignant melanoma. However, these results taken together with other studies provide the first indications for a tumor suppressor role of Hugl-1 gene in human malignant melanoma.
This study further revealed that Hugl-1 expression has an impact on the expression of MMPs and cell-cell adhesion molecules. Especially molecules involved in EMT such as MMP-9, MMP-14 and E-cadherin (Pla et al., 2001 ) and also notch4, fibronectin and b-catenin (Gilles et al., 1997a, b; Tester et al., 2000; Kuphal et al., 2005) were shown to be regulated by Hugl-1. Interestingly, lgl homozygous mutants in Drosophila show a loss of apical-basal polarity and loss of structure of epithelial tissues (Humbert et al., 2003) . Additionally, mutant tissues exhibit changes in adhesion and an increased ability to migrate and invade (Agrawal et al., 1995) . Interestingly, Hugl-1 was detectable by immunofluorescence in the cytoplasm and the membranes in cell lines expressing Hugl-1. This translocation to the membrane coincides with re-expression of Ecadherin. Recent studies support this finding as MDCK cells showed a relocalization of lgl from the cytoplasm to membranes upon establishment of polarization (Musch et al., 2002) .
Under normal homeostasis, melanocyte growth and behavior is tightly controlled by the surrounding keratinocytes (Bogenrieder and Herlyn, 2003; Berking et al., 2004; Haass et al., 2004; Li et al., 2004) . Keratinocytes regulate melanocyte behavior through a complex system of paracrine growth factors and cell-cell adhesion molecules. It is well known that physiological (as EMT, wound healing) or pathological changes, leading to development of malignant melanoma, influence this homeostatic balance and can lead to altered expression of cell-cell adhesion and cell-cell communication molecules. In particular, there is a switch from the E-cadherin-mediated keratinocytemelanocyte partnership to the N-cadherin-mediated melanoma-melanoma and melanoma-fibroblast interaction. As shown in this study, Hugl-1 seems to play a role in this process. These findings suggest that lgl/ Hugl play a role in EMT in Drosophila and in human tissues.
Additionally, Lgl was recently found to inhibit notch signaling (Justice et al., 2003) . Until now the mechanism of this regulation is not clear, but it is speculated that Lgl is required to target notch inhibitors to the right localization in the cell. In malignant melanoma upregulation of notch signaling was found (Nickoloff et al., 2003; Hoek et al., 2004) , which coincides with the loss of Hugl-1 expression presented in this study.
In summary, the development of malignant melanoma is associated with decreased cell-cell contact to the surrounding keratinocytes in the epidermis as an early event in tumor development. The available biochemical information on Hugl proteins from studies in Drosophila and cultured human cells support the notion that Hugl-1 contributes to maintenance of epithelial integrity through its cytoskeletal interactions. Taken together with the results presented in this paper, increasing evidence is accumulating for the role of Hugl-1 during human cancer progression. Thus, further investigations are warranted to understand the mechanisms that lead to the inactivation of Hugl-1.
Materials and methods

Cell culture
The melanoma cell lines Mel Im, Mel Ei, Mel Wei, Mel Ho, Mel Juso, Mel Ju, SK Mel 28, and HTZ19d and B16 were described previously (Jacob et al., 1995) . The cell lines Mel Ei, Mel Wei, Mel Ho and Mel Juso were derived from a primary cutaneous melanoma, Mel Im, Mel Ju, SK Mel 28, and HTZ19d were derived from metastases of malignant melanomas and B16 was derived from primary melanoma in mice. Cells were maintained in DMEM supplemented with penicillin (400 U/ml), streptomycin (50 mg/ml), L-glutamine (300 mg/ml) and 10% fetal calf serum (FCS; Sigma, Deisenhofen, Germany) and split at a 1:5 ratio every 3 days. Human primary melanocytes derived from normal skin were cultivated in melanocyte medium MGM-3 (Gibco, Eggenstein, Germany) under a humified atmosphere of 5% CO 2 at 371C. Cells were used in passages 6-10 and not later than 3 days after trypsinization. Cells were detached for subcultivation or assay with 0.05% trypsin and 0.04% EDTA in PBS. Cell proliferation was determined using the XTT assay (Roche, Mannheim, Germany). 5-azacytosine treatment for analysis of promoter methylation was performed as previously described (Behrmann et al., 2003) .
RNA isolation and reverse transcription
Total cellular RNA was isolated from cultured cells or from microdissected tissues using the RNeasy kit (QIAGEN, Hilden, Germany). Laser microdissection was performed using a PALM microlaser system (P.A.L.M. Microlaser Technologies AG, Bernried, Germany) under the supervision of a pathologist; isolated samples were verified to be melanoma by RT-PCR of melanoma biomarkers. cDNAs were generated by reverse transcriptase reaction performed in 20 ml reaction volume containing 2 mg of total cellular RNA, 4 ml of 5 Â first-strand buffer (Invitrogen, Groningen, The Netherlands), 2 ml of 0.1 M DTT, 1 ml of dN 6 -primer (10 mM), 1 ml of dNTPs (10 mM) and DEPC water. The reaction mixture was incubated for 10 min at 701C, 200 U of Superscript II reverse transcriptase (Invitrogen) were added and RNAs were transcribed for 1 h at 371C. Reverse transcriptase was inactivated at 701C for 10 min and the RNA was degraded by digestion with 1 ml RNase A (10 mg/ml) at 371C for 30 min.
Expression analysis
RT-PCR analysis of Hugl-1 was performed using specific primers (Hugl-1-forward: 5 0 -AAG CTG TGG GCC CGC ATT GTG A-3 0 and Hugl-1-reverse: 5 0 -GTC CTG GAG GAG GTC TAT GAT A-3 0 (450 bp fragment)). The PCR reaction was performed in a 100 ml reaction volume containing 5 ml 10 Â Taq-buffer, 1 ml of cDNA, 1 ml of each primer (20 mM), 0.5 ml of dNTPs (10 mM), 0.5 U of Taq polymerase and 41 ml of water. The amplification reactions were performed by 33 cycles of 1 min at 941C, 1 min at 621C and a final extension step at 721C for 1.5 min. The PCR products were resolved on 1.5% agarose gels.
Analysis of expression by quantitative PCR
Quantitative real-time-PCR was performed on a Lightcycler (Roche, Mannheim, Germany). cDNA template (2 ml), 2 ml 25mM MgCl 2 , 0.5 ml (20 mM) of forward and reverse primers and 2 ml of SybrGreen LightCycler Mix in a total of 20 ml were applied to the following PCR program: 30 s 951C (initial denaturation); 201C/s temperature transition rate up to 951C for 15 s, 3 s 681C, 5 s 721C, 811C acquisition mode single, repeated 40 times (amplification). The PCR reaction was evaluated by melting curve analysis and checking the PCR products on 1.8% agarose gels. Expression of the following genes was analysed: Hugl-1, E-Cadherin, notch4, fibronectin, b-catenin, mMP-9 and MMP-14 (primer sequences obtained from Clontech (BD Biosciences, Heidelberg, Germany).
Immunofluorescence
Melanoma cell lines and Mel Im cell clones were grown on eight well chamber slides for two days, fixed with 70% methanol for 15 min, washed with PBS/0.1% Triton X and covered with blocking solution (PBS/0.1% Triton X/3% BSA) for 1 h. Thereafter, cells were incubated with a polyclonal rabbit-anti-Hugl-1 antibody (1:1000; Strand et al., 1995) or an E-cadherin antibody (Takara, 1:1000), respectively, overnight at 41C. After washing the cells, they were incubated with the secondary antibody (Cy3-conjugated Affinipure goat antirabbit IgG F(ab) antibody (1:1000, Jackson Immunoresearch, USA)) and Hoechst 33 342 (1:5000, Molecular Probes, USA) for 30 min. After mounting, images were collected by laser scanning micrcoscopy.
Immunohistochemistry
Paraffin-embedded preparations of normal skin, five nevi (three junctional, two dermal), five primary and five metastases of malignant melanomas were screened for Hugl-1 protein expression by IHC. The tissues were deparaffinized, rehydrated and subsequently incubated with primary polyclonal rabbit Hugl-1 antibody (1:500) over night at 41C. The secondary antibody (biotin-labelled anti-rabbit, DAKO, Germany) was incubated for 30 min at room temperature, followed by incubation with streptavidin-POD (DAKO) for 30 min. Antibody binding was visualized using AEC solution (DAKO). Finally, the tissues were counterstained by haemalaun solution (DAKO). The evaluation of the staining was performed semiquantitatively by lightmicroscopy. The intensity of staining was graded as follows: negative: 0; weak: 1; medium: 2; strong: 3.
Stable transfection of melanoma cells with Hugl-1 A panel of Mel Im cell clones expressing Hugl-1 was established by stable transfection with sense expression plasmid. Plasmids were cotransfected with pcDNA3 (Invitrogen), containing the selectable marker for neomycin resistance. Controls received pcDNA3 alone. Transfections were performed using lipofectamin plus (Invitrogen). 1 day after transfection, cells were placed into selection medium containing 50 mg/ml G418 (Sigma). After 25 days of selection, individual G418-resistant colonies were subcloned.
Western blot analysis 3 Â 10 6 cells were lysed in 200 ml RIPA buffer (Roche) and incubated for 15 min at 41C. Insoluble fragments were removed by centrifugation at 13 000 r.p.m. for 10 min and the supernatant lysate was immediately shock frozen and stored at À801C. RIPA-cell lysate was loaded and separated on SDS-PAGE gradient gels (Invitrogen) and subsequently blotted onto a PVDF membrane. After blocking for 1 h with 3% BSA/ PBS, the membrane was incubated for 16 h with the primary antibody (polyclonal rabbit-anti-Hugl-1 antibody (1:2000)), E-cadherin (Tranduction Lab, 1:2500) and beta-actin (Sigma, 1:2500). Then the membrane was washed three times in PBS, incubated for 1 h with 1:3000 of an alkaline phosphate-coupled secondary antibody (Chemicon) and then washed again. Finally, immunoreactions were visualized by NBT/BCIP (Sigma) staining.
Migration and invasion assay
Migration and invasion assays were performed using Boyden Chambers containing polycarbonate filters with 8 mm pore size (Costar, Bodenheim, Germany), essentially as described previously (Jacob et al., 1995) . Filters were coated with gelatine or Matrigel (diluted 1:3 in H 2 O; Becton Dickinson, Heidelberg, Germany). The lower compartment was filled with fibroblast-conditioned medium, used as a chemoattractant. Melanoma cells were harvested by trypsinization for 2 min, resuspended in DMEM without FCS at a density of 2 Â 10 5 cells/ml and placed in the upper compartment of the chamber. After incubation at 371C for 4 h, the filters were collected and the cells adhering to the lower surface fixed, stained and counted.
Anchorage-independent growth assay Cells were seeded into six-well plates in DMEM, 0.36% agar (Sigma), supplemented with 10% FCS on top of a 0.72% agar bed in similar medium. The cultures were incubated for 14 days and the colonies were measured and photographed. Colony size was measured using a Carl Zeiss microscope (Carl Zeiss Vision GmbH, Hallbergmoos, Germany). For each cell clone the diameter of 20 colonies was determined and statistics was performed.
Migration assay
Migration of cells was assayed by scratch assays. For scratch assays ('wound-healing assay'), cells were seeded in high density into six-well plates and scratched by a pipette tip in a definite array. Migration into this array was documented and measured after 24 and 48 h. Each analysis was performed in triplicate.
Attachment assays
Attachment assays were performed in 96-well plates. Melanoma cells were harvested by trypsinization for 2 min, resuspended in DMEM without FCS at a density of 2 Â 10 5 cells/ml and placed in the well. Cells attached after 15 min were counted.
Statistical analysis
Results are expressed as mean7s.d. (range) or percent. Comparison between groups was made using Student's paired t-test. A P-value o0.05 was considered statistically significant. All calculations were performed using the GraphPad Prism software (GraphPad software Inc., San Diego, USA).
Abbreviations bp, base pair; Hugl, human giant larvae; lgl, lethal giant larvae; PCR, polymerase chain reaction; RT, reverse transcription; EMT, epithelial-mesenchymal transition; MMP, matrix metalloproteinase; NHEM, normal human epidermal melanocytes; NDP, nucleoside diphosphate kinase; IHC, immunohistochemistry; PKC, protein kinase C; Par 6, protease-activated receptor 6.
